Playing catch-up to its other cardiovascular device rivals, Boston Scientific Corp. is investing in the mitral valve repair space by putting money into Millipede, a California start-up that has developed the IRIS transcatheter annuloplasty ring system.
Boston Scientific paid $90m for a stake in Santa Rosa-based Millipede. Additionally, the cardiovascular company has taken an option to acquire the rest of Millipede at any time prior to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?